AlphaNooner by AdvisorShares

Nicholas Sosiak, COO & CFO of Cannara Biotech (TSX: LOVE), joins AlphaNooner to discuss the company's latest Q3 results and new partnership with Curaleaf. We'll explore what drove the quarter, how the partnership expands Cannara's opportunity, and what management sees as the biggest catalysts for the business going forward. AlphaNooner by AdvisorShares brings you timely conversations with inve...

Ken Hyman and Matt Heimann of CreativeOne Wealth discuss why traditional balanced portfolios are evolving, how they seek equity-like returns with built-in risk management, and what a modern portfolio looks like in today's market. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and...

John Lewis of Nasdaq Dorsey Wright joins AlphaNooner to discuss what relative strength is signaling across domestic and international markets in July 2026. John explains why returns have been concentrated in the market's top momentum names, what shifted over the past month, how trend-following can help investors identify leadership, and where relative weakness may point to opportunities on the sho...

Healthcare innovation has been one of the biggest investment stories of the year. Psychedelic biotech is moving from a speculative theme to one attracting major pharmaceutical capital, while the cannabis industry continues to make progress following the conclusion of the DEA's Schedule III hearings. AdvisorShares' Dan Ahrens joins AlphaNooner to look at what's driving both themes, where investors...

Ron Piccinini returns to AlphaNooner to share how he's reading the current market setup more than halfway through 2026. We discuss how to evaluate risk while still participating in market upside, why a disciplined, rules-based process matters when headlines and narratives keep shifting, and what could drive markets as attention turns toward the midterms. AlphaNooner by AdvisorShares brings you tim...

Hirsh Jain, Founder of Ananda Strategy, joins the AlphaNooner to discuss the next phase of cannabis investing following the conclusion of the federal rescheduling hearings. He'll break down the evolving regulatory landscape, operator fundamentals, and where he sees the biggest opportunities emerging across the industry. Widely recognized for his work at the intersection of cannabis policy, capital...

Eddy Elfenbein, founder of Crossing Wall Street, joins AlphaNooner to break down the biggest forces driving today's market, from shifting leadership and earnings expectations to the Fed, economic data, and where he's finding opportunity as investors navigate the second half of 2026. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers...

Todd Harrison, Founding Partner and CIO of CB1 Capital, joins AlphaNooner from outside DEA headquarters as the federal cannabis rescheduling hearings wrap up. We discuss where the cannabis industry stands today, the parallel regulatory processes underway for medical and adult-use cannabis, and what the hearings could mean for investors. Todd also shares his framework for the catalysts that matter...

As the DEA rescheduling hearings wrap up, Dan Ahrens breaks down what investors should watch next, the industry's biggest catalysts, and how cannabis is continuing to evolve. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next. Watch the full vi...

Join Jeffrey Hirsch, Editor-in-Chief of the Stock Trader's Almanac, as he shares decades of market wisdom, seasonal investing strategies, historical market trends, and practical insights to help investors make more informed decisions. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment theme...

AlphaNooner is back on location at DEA headquarters with another update from inside the federal cannabis rescheduling hearing. We break down the latest testimony from a DEA special agent covering claims about criminal organizations, cannabis-impaired driving and traffic safety, and environmental concerns such as pesticide use in illicit grows. We share our takeaways on how these arguments stack up...

AdvisorShares CEO Noah Hamman joins AlphaNooner for a midweek check-in on what matters in markets today. With geopolitical tensions in the Middle East back in the headlines and volatility returning, we discuss how investors can think about the macro backdrop, market reactions to global events, and the latest developments around federal cannabis rescheduling. AlphaNooner by AdvisorShares brings you...

Matthew "Whiz" Buckley, CEO of TopGun Options and former Navy TOPGUN fighter pilot, breaks down today's market, the options trades on his radar, disciplined risk management, and the lessons every trader can apply. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories sha...

AlphaNooner reports from Virginia at the midpoint of the DEA's administrative hearing on federal cannabis rescheduling. We share what we've seen and heard inside the proceedings so far, including expert testimony from Harvard psychobiology professor Dr. Bertha Madras on addiction and the case being made against rescheduling. We walk through the key arguments on the record, from how cannabis differ...

George Hodgin, Founder and CEO of BRC Therapeutics, joins AlphaNooner to discuss the next frontier of cannabinoid medicine. We'll explore how BRC is navigating the FDA drug approval process, why pharmaceutical-grade cannabinoids could reshape pain management and other unmet medical needs, and what investors should know as cannabis evolves from a consumer product into a biotech opportunity. George...

Dan Ahrens joins AlphaNooner to discuss the themes shaping markets right now, from cannabis uplistings and industry consolidation to psychedelic healthcare breakthroughs, AI infrastructure, industrials, and where capital is flowing. We'll explore what's changing beneath the surface, which trends may have staying power, and what investors should be watching in the second half of 2026. AlphaNooner b...

Sue Taylor, founder of Mama Sue Wellness and Co-Founder of The Farmacy, joins AlphaNooner to share her journey from Catholic school principal to one of cannabis' most trusted educators. We'll discuss senior wellness, breaking decades of stigma, building a cannabis brand around education, her partnership with Glass House Brands, and why trust may be the industry's greatest asset. AlphaNooner by Adv...

Virginia may be entering the next chapter of the U.S. cannabis story. After lawmakers approved legislation to establish a regulated adult-use market, one of the nation's largest untapped cannabis opportunities is back in focus. At the same time, the DEA's administrative hearing on federal cannabis rescheduling begins June 29, making this one of the most consequential weeks for the industry in year...

Ron Piccinini joins AlphaNooner to break down how investors can think about risk management in today's market environment. From volatility signals and downside protection to staying invested during uncertain conditions, Ron discusses how portfolio construction has evolved and why managing drawdowns may matter just as much as capturing upside in 2026. AlphaNooner by AdvisorShares brings you timely...

Noah Hamman and Mackenzie Peterson break down the latest developments in the federal cannabis rescheduling process, including the recent administrative stay, what it means procedurally, and what still needs to happen as the process moves forward. They discuss the October 13 timeline, the steps that could follow, and whether the latest developments change the broader cannabis investment thesis. Plu...

Dan Ahrens joins the AlphaNooner to discuss the themes shaping markets right now, from cannabis uplistings and industry consolidation to psychedelic healthcare breakthroughs, AI infrastructure, industrials, and where capital is flowing. We'll explore what's changing beneath the surface, which trends may have staying power, and what investors should be watching in the second half of 2026.

Sammy Armenia, VP of Corporate Development at C21 Investments,  joins Mackenzie Peterson to discuss C21's planned transaction with Vireo Growth, why consolidation is accelerating across cannabis, and what the next generation of industry leaders may look like. Are we entering a new era where scale, capital access, and operational depth matter more than ever? Which markets are becoming most strategi...